Korean J Radiol.  2016 Feb;17(1):93-102. 10.3348/kjr.2016.17.1.93.

Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis

• Wang X
• Hu Y
• Ren M
• Lu X
• Lu G
• He S

• KMID: 2351168
• DOI: http://doi.org/10.3348/kjr.2016.17.1.93

Abstract

OBJECTIVE
To compare the efficacy and safety of combined radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) with RFA alone for hepatocellular carcinomas (HCC).
MATERIALS AND METHODS
Randomized controlled trial (RCT) studies that compared the clinical or oncologic outcomes of combination therapy of TACE and RFA versus RFA for the treatment of HCC were identified through literature searches of electronic databases (Pubmed, Embase, Cochrane Library, China Biology Medicine disc, China National Knowledge Infrastructure, and Google Scholar). Hazard ratios (HRs) or odds ratios (ORs) with their corresponding 95% confidence interval (CI) were combined as the effective value to assess the summary effects. The strength of evidence was rated by the Grading of Recommendations Assessment, Development, and Evaluation system.
RESULTS
Six RCTs with 534 patients were eligible for inclusion in this meta-analysis. The meta-analysis showed that the combination of TACE and RFA is associated with a significantly longer overall survival (HR = 0.62, 95% CI: 0.49-0.78, p < 0.001) and recurrence-free survival (HR = 0.55, 95% CI: 0.40-0.76, p < 0.001) in contrast with RFA monotherapy. The seemingly higher incidence of major complications in the combination group compared with RFA group did not reach statistical significance (OR = 1.17, 95% CI: 0.39-3.55, p = 0.78).
CONCLUSION
In patients with HCC, the combination of TACE and RFA is associated with significantly higher overall survival and recurrence-free survival, as compared with RFA monotherapy, without significant difference in major complications.

Keyword

Transcatheter arterial chemoembolization; Radiofrequency ablation; Hepatocellular carcinomas; Meta-analysis

MeSH Terms

Carcinoma, Hepatocellular/*surgery
Catheter Ablation/adverse effects/*methods
Chemoembolization, Therapeutic/adverse effects/*methods
China
Combined Modality Therapy
Disease-Free Survival
Humans
Liver Neoplasms/*surgery
Odds Ratio
Proportional Hazards Models
Treatment Outcome

Figure

• 

  Fig. 1 Assessment of risk of bias in this meta-analysis. A. Summary of risk of bias for each trial assessed by Cochrane Collaboration's tool. B. Risk of bias graph about each risk of bias item presented as percentages across all included studies.

• 

  Fig. 2 Comparative OS in response to combination of RFA and TACE vs. RFA alone for HCC. All 6 randomized controlled trials including 534 patients provided OS information. Cumulative OS in TACE-RFA combined group was significantly longer than RFA alone group. CI = confidence interval, HCC = hepatocellular carcinomas, OS = overall survival, RFA = radiofrequency ablation, SE = standard error, TACE = transcatheter arterial chemoembolizaton

• 

  Fig. 3 Comparative RFS in response to combination of RFA and TACE vs. RFA alone for HCC. Meta-analysis demonstrated that RFA plus TACE therapy was associated with significantly higher RFS than that RFA monotherapy. CI = confidence interval, HCC = hepatocellular carcinoma, RFA = radiofrequency ablation, RFS = recurrence-free survival, SE = standard error, TACE = transcatheter arterial chemoembolizaton

• 

  Fig. 4 Comparison of major complications in response to combination of RFA and TACE vs. RFA alone for HCC. Meta-analysis indicated that combination group had higher incidence of major complications, as compared with monotherapy group, but difference between these 2 groups had no statistical significance. CI = confidence interval, HCC = hepatocellular carcinoma, RFA = radiofrequency ablation, TACE = transcatheter arterial chemoembolizaton

• 

  Fig. 5 Funnel plot of publication bias for OS. All 6 eligible randomized controlled trials reported relative data on OS. Funnel plot of OS shaped with bilateral symmetry indicated lack of publication bias. OS = overall survival, SE = standard error

Reference

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87–108.

2. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004; 126:1005–1014.

3. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005; 129:122–130.

4. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010; 52:762–773.

5. N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, Coderc E, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009; 50:1475–1483.

6. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology. 2000; 214:761–768.

7. McGhana JP, Dodd GD 3rd. Radiofrequency ablation of the liver: current status. AJR Am J Roentgenol. 2001; 176:3–16.

8. Idée JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013; 88:530–549.

9. Maluccio MA, Covey AM, Porat LB, Schubert J, Brody LA, Sofocleous CT, et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2008; 19:862–869.

10. Min JH, Lee MW, Cha DI, Jeon YH, Shin SW, Cho SK, et al. Radiofrequency ablation combined with chemoembolization for intermediate-sized (3-5 cm) hepatocellular carcinomas under dual guidance of biplane fluoroscopy and ultrasonography. Korean J Radiol. 2013; 14:248–258.

11. Takaki H, Yamakado K, Uraki J, Nakatsuka A, Fuke H, Yamamoto N, et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm. J Vasc Interv Radiol. 2009; 20:217–224.

12. Chang NK, Shin SS, Kim JW, Kim HJ, Jeong YY, Heo SH, et al. Effect of ultrasound-guided radiofrequency ablation in incompletely treated hepatocellular carcinoma after transcatheter arterial chemoembolization. Korean J Radiol. 2012; 13:Suppl 1. S104–S111.

13. Kim JW, Shin SS, Kim JK, Choi SK, Heo SH, Lim HS, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean J Radiol. 2013; 14:626–635.

14. Hu YQ. Radiofrequency ablation and transcatheter arterial chemoembolization in primary hepatic carcinoma. Contemp Med. 2011; 17:39–40.

15. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011; 98:1210–1224.

16. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009; 252:905–913.

17. Kang CB, Xu HB, Wang SL, Rui JA. Treatment of large hepatoma by TACE in combination with RFA. Zhonghua Gandan Waike Zazhi. 2007; 13:828–830.

18. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928.

19. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336:924–926.

20. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17:2815–2834.

21. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16.

22. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration Web site;Published September 2009. http://www.cochrane-handbook.org.

23. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013; 31:426–432.

24. Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology. 2012; 262:689–700.

25. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010; 116:5452–5460.

26. Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther. 2008; 25:787–794.

27. Aikata H, Shirakawa H, Takaki S, Uka K, Miki D, Yamashina K, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinomas. Hepatology. 2006; 44:494A.

28. Lin JJ, Wu W, Jiang XF, Jin XJ, Lu LJ, Bao LW. [Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience]. Zhonghua Zhong Liu Za Zhi. 2013; 35:144–147.

29. Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008; 299:1669–1677.

30. Shen SQ, Xiang JJ, Xiong CL, Wu SM, Zhu SS. Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC. Hepatogastroenterology. 2005; 52:1403–1407.

31. Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. [Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation]. Ai Zheng. 2005; 24:827–833.

32. Shibata T, Shibata T, Maetani Y, Isoda H, Hiraoka M. Radiofrequency ablation for small hepatocellular carcinoma: prospective comparison of internally cooled electrode and expandable electrode. Radiology. 2006; 238:346–353.

33. Jiang G, Xu X, Ren S, Wang L. Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma. Tumour Biol. 2014; 35:3405–3408.

34. Goldberg SN, Girnan GD, Lukyanov AN, Ahmed M, Monsky WL, Gazelle GS, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology. 2002; 222:797–804.

35. Seki T, Tamai T, Nakagawa T, Imamura M, Nishimura A, Yamashiki N, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer. 2000; 89:1245–1251.

36. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2013; 19:3872–3882.

37. Lu Z, Wen F, Guo Q, Liang H, Mao X, Sun H. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol. 2013; 25:187–194.

38. Kong QF, Jiao JB, Chen QQ, Li L, Wang DG, Lv B. Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma. Tumour Biol. 2014; 35:2655–2659.

39. Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci. 2012; 57:3026–3031.

40. Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci. 2013; 58:2107–2113.

41. Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010; 30:741–749.

42. Liu Z, Gao F, Yang G, Singh S, Lu M, Zhang T, et al. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol. 2014; 35:7407–7413.

43. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004; 48:2787–2792.